Where does Kala Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Kala Pharmaceuticals, Inc. ranks #6,451 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Kala Pharmaceuticals, Inc. hold?

Kala Pharmaceuticals, Inc. holds 52 US utility patents granted between 2015 and 2023, spanning 5 technology areas.

What is Kala Pharmaceuticals, Inc.'s Innovation Score?

Kala Pharmaceuticals, Inc. has an Innovation Score of 36.7 out of 100 (top 46% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Kala Pharmaceuticals, Inc. focus on?

Kala Pharmaceuticals, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 46 patents, ranking #177 of 3,165 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Kala Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Kala Pharmaceuticals, Inc.'s recent grant velocity is -42% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Kala Pharmaceuticals, Inc.'s patents?

Kala Pharmaceuticals, Inc.'s patents average 22.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Kala Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Kala Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 52 granted patents across 5 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Kala ranks #6,451 of 49,997 tracked US assignees by granted-patent volume, with 52 patents across 5 technology areas.

#6,451
of 49,997 US assignees by volume: Top 46%
by Innovation Score (36.7/100): 22.9
avg claims per patent: -42%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6451 · US Corporation #6,451 · 52 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 52 grants
UPPER-Q #6,451/49,997
PHOTO-FINISH JBF Interlude 2009
CPC-NARROW C07D · 5 areas
INNOV-THIN 36.7/100
CLAIMS-DENSE 22.9 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -42% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: JBF Interlude 2009 Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Kala’s 36.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.7 pts (37%) Velocity 1.3 pts (4%) Breadth 7.9 pts (22%) Claim depth 13.7 pts (37%)

Qualcomm Incorporated · highest

85
Centrix · near

37
E-One · near

37
Fremonta · near

37
GeneSic Semiconductor · near

37
Kala Pharmaceuticals · this assignee

37
3D Lighting… · lowest

7

What this shows Kala's Innovation Score is 36.7/100 (top 46% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Kala?

Each dot is one of Kala’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Kala’s own 22.9 claims/patent is ABOVE the 10.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Kala vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Kala's grants concentrate

Kala Pharmaceuticals, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 88.5% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2019 (11 grants) versus a trough of 1 in 2023. By volume, Kala sits between JBF Interlude 2009 Ltd and Lumson S.p.A..

Kala's three-year grant acceleration

From 2019–2021 to 2022–2024, Kala Pharmaceuticals, Inc. moved from 25 to 5 grants (0.20x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

JBF Interlude 2009

52
Jenoptik Optical…

52
Kyowa Hakko BIO

52
Kyushu University

52
King Furniture Au…

52
Lanzatech New Zea…

52
Limagrain Europe

52
Lumson S p A

52
Kala Pharmaceutic… ◀

52

What this shows Kala holds 52 patents at rank #6,453, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Kala

By rank, the assignees closest to #6,453 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Kala's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Kala, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Kala ranks #177 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (37 here).

GeneSic Semiconductor Inc. 37 Fremonta Corporation 37 E-One, Inc. 37 Centrix Inc. 37

Similar claim depth

Nearest assignees by average claims per patent (22.9 here).

Versata Development Group, Inc. 22.9 avg Theatro Labs, Inc. 22.9 avg Motive Drilling Technologies, Inc. 22.9 avg Cardioinsight Technologies Inc. 22.9 avg

Kala's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 46% higher than 54% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Kala Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	3.8%
2016	5	9.6%
2017	9	17.3%
2018	6	11.5%
2019	11	21.2%
2020	8	15.4%
2021	6	11.5%
2022	4	7.7%
2023	1	1.9%

Which technologies does Kala Pharmaceuticals, Inc. patent most?

C07D - Heterocyclic Compounds 46

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 40

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 37

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 16

Y02A - Technologies FOR Adaptation TO Climate Change 8

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Kala Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Kala Pharmaceuticals, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 88.5% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #6,451 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Kala Pharmaceuticals, Inc. against JBF Interlude 2009 Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.